Investors in RARE Can Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit

Investor rights law firm Rosen Law Firm is notifying individuals who acquired Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023, and December 26, 2025, inclusive (referred to as the “Class Period”), regarding the significance of the lead plaintiff deadline on April 6, 2026. If you bought Ultragenyx common stock during this period, you could potentially receive compensation without incurring any out-of-pocket expenses through a contingency fee agreement. To participate in the Ultragenyx class action, interested individuals are advised to either visit a specified website or reach out to Phillip Kim, Esq. through a toll-free number or email for further details on how to partake in the class action. It is crucial to note that a class action lawsuit has already been initiated, and individuals seeking to serve as lead plaintiff must take action and liaise with the Court no later than April 6, 2026. The role of a lead plaintiff entails representing other class members in overseeing the lawsuit.

Rosen Law Firm underscores the importance of engaging reputable legal representation with a proven track record of success in leadership capacities. It is essential for investors to align themselves with law firms that possess the requisite expertise, resources, and relevant experience to effectively navigate such legal matters. Oftentimes, entities issuing notices may lack the same level of proficiency, resources, or credibility as established legal firms, thereby underscoring the importance of carefully selecting qualified counsel to advocate on one’s behalf in such proceedings.